Global Remicade Biosimilar Market Size By Type (100mg/10ml, 500mg/50ml), By Application (Blood Disorders, Oncology Diseases), By Region, And Segment Forecasts, 2023 to 2032

The Global Remicade Biosimilar Market was valued at USD 2.1 billion in 2023 and is projected to reach USD 6.5 billion by 2031, growing at a CAGR of 15.0% during the forecast period from 2023 to 2031. This robust growth is driven by the increasing prevalence of autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis, combined with the rising need for cost-effective biologic therapies. As healthcare systems globally face rising costs, Remicade biosimilars are gaining traction due to their ability to offer similar efficacy at lower prices, fueling market expansion across both developed and developing economies.

Drivers:

Rising Incidence of Autoimmune Diseases:

The global burden of autoimmune conditions continues to rise, necessitating long-term immunosuppressive treatments. Remicade biosimilars provide an effective and affordable alternative, promoting broader patient access.

Patent Expiry and Cost Pressure:

The expiry of patent protection for infliximab (Remicade) has opened up opportunities for biosimilar manufacturers. Healthcare providers are increasingly opting for biosimilars to reduce treatment costs without compromising efficacy.

Government and Payer Support:

Regulatory agencies in regions like Europe and North America are streamlining biosimilar approval pathways and encouraging their use via substitution policies and reimbursement incentives.

Restraints:

Physician and Patient Reluctance:

Despite proven clinical equivalence, hesitancy among healthcare professionals and patients to switch from original biologics to biosimilars continues to challenge adoption in certain markets.

Complex Manufacturing Processes:

Biosimilar development involves sophisticated biotechnological processes. Any variability can affect product consistency and safety, posing manufacturing and regulatory hurdles.

Opportunity:

Expansion in Emerging Markets:

Rapidly growing healthcare infrastructure in Asia-Pacific, Latin America, and Africa offers untapped potential. Government initiatives to reduce drug spending are fostering biosimilar uptake in these regions.

Advancements in Biosimilar Development:

Innovations in analytical techniques and biologics manufacturing are lowering development costs and improving biosimilar quality, opening doors for new market entrants and faster approvals.

Market by System Type Insights:

Based on system type, the Infliximab-dyyb (Inflectra) segment led the market in 2023. Inflectra has established strong market presence in North America and Europe owing to early entry and positive clinical outcomes. Other biosimilars like Renflexis (infliximab-abda) and Avsola (infliximab-axxq) are gaining market share, benefiting from payer preference and expanding distribution networks.

Market by End-use Insights:

In 2023, Hospital Pharmacies accounted for the largest revenue share. Their centralized procurement models and participation in bulk biosimilar purchase agreements drive substantial uptake. Retail Pharmacies are witnessing growing demand as more biosimilars are authorized for at-home treatment, improving patient access.

Market by Regional Insights:

Europe dominated the global Remicade biosimilar market in 2023 due to early adoption policies, strong biosimilar infrastructure, and favorable regulatory frameworks. North America follows closely, supported by increasing trust in biosimilars and active payer involvement. Meanwhile, Asia-Pacific is expected to register the fastest growth due to expanding healthcare coverage and localized biosimilar production initiatives.

Competitive Scenario:

Key players in the Remicade biosimilar market include Pfizer Inc. (Inflectra), Samsung Bioepis and Merck & Co. (Renflexis), Amgen Inc. (Avsola), Celltrion Healthcare, and Biocon Biologics. These companies are investing in production capacity expansion, regulatory approvals across multiple countries, and strategic alliances to strengthen global distribution networks.

Recent Developments:

In 2023, Amgen expanded the market availability of Avsola in key Asia-Pacific regions following successful clinical trials.

Pfizer announced a pricing realignment strategy for Inflectra in Europe to remain competitive amid new market entrants.

Samsung Bioepis received Health Canada’s approval for expanded indications of Renflexis in 2024.

Scope of Work – Global Remicade Biosimilar Market

Key Market Developments:

June 2023: Inflectra surpassed USD 1 billion in cumulative global sales, reflecting strong payer support in the U.S. and EU.

February 2024: Renflexis received extended indication approval for pediatric Crohn’s disease in Europe.

April 2025: Biocon Biologics partnered with regional distributors in Southeast Asia to enhance biosimilar penetration.

FAQs:

1) What is the current market size of the Global Remicade Biosimilar Market?

The market was valued at USD 2.1 billion in 2023.

2) What is the major growth driver of the Global Remicade Biosimilar Market?

The primary growth driver is the rising demand for cost-effective treatments for autoimmune diseases, supported by patent expiry and healthcare cost pressures.

3) Which is the largest region during the forecast period in the Global Remicade Biosimilar Market?

Europe holds the largest share due to favorable regulatory frameworks and high adoption rates.

4) Which segment accounted for the largest market share in the Global Remicade Biosimilar Market?

Infliximab-dyyb (Inflectra) accounted for the largest market share in 2023.

5) Who are the key market players in the Global Remicade Biosimilar Market?

Major players include Pfizer, Amgen, Samsung Bioepis, Merck & Co., Celltrion Healthcare, and Biocon Biologics.